RxDoctor Payments Data

Daniel Pace, MD

Family Medicine · Searcy, ARNPI 1972567758

Payments from drug & device makers

$1,595in general payments, 2019–2025

Across 93 payments — averaging $17.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$331
  • AbbVie$325
  • Amgen$152
  • Pfizer$143
  • Novo Nordisk$128
  • Astellas Pharma US Inc$121
  • plus $394 from 11 others

What the payments were for

  • Food & beverage$1,44591%
  • Education$1509%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,595 in reported general payments places this provider in the 65th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$176,801
Medicare patients
573
Services billed
2,491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide254$259,419
MounjaroTirzepatide113$122,091
EliquisApixaban126$92,426
LinzessLinaclotide68$50,740
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$47,353
JardianceEmpagliflozin35$30,505
JanuviaSitagliptin Phosphate46$27,967
XareltoRivaroxaban21$26,124
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog46$22,294
UbrelvyUbrogepant21$21,821
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$18,637
Janumet XrSitagliptin Phos/Metformin Hcl16$18,512
Tresiba Flextouch U-200Insulin Degludec15$16,109
FarxigaDapagliflozin Propanediol21$15,153
Tresiba Flextouch U-100Insulin Degludec23$13,809

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$128$259,419254 claims
Lilly USA, LLCMounjaro$43$122,091113 claims
PfizerEliquis$143$92,426126 claims
AbbVieLinzess, Ubrelvy$325$72,56289 claims
GSKTrelegy Ellipta, Breo Ellipta$331$50,82474 claims
Boehringer IngelheimJardiance$33$30,50535 claims
Johnson & JohnsonXarelto$65$26,12421 claims
AstraZenecaFarxiga, Symbicort$45$20,35343 claims
Astellas Pharma US IncMyrbetriq$121$10,48123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Searcy

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →